Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
Vancouver, Canada, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Year: 2025
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four...
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
Ra’anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing...
NTA Implant: Solidifying Global Leadership with MDR Certification and Launching a New Era in Implantology
EGOLZWIL, Switzerland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- NTA Implant, a leading brand of the Switzerland-based Pilatus Swiss Dental GmbH,...
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025...
Jushi Holdings Inc. Announces Grand Opening of Beyond Hello™ Parma in Ohio, Expanding its Statewide Retail Footprint
Sixth Beyond Hello Location in Ohio and 41st Retail Location NationwideNew Dispensary Opens September 19th in Parma, Just South of...
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in...
Spectral AI Named to TIME’s List of World’s Top HealthTech Companies 2025
DALLAS, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence...
Vaxart Announces Withdrawal of Reverse Stock Split Proposal
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage...
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need...
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with...
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG...
SAB BIO Highlights Data in Multiple Presentations at EASD
-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an...
Kraig Biocraft Laboratories Expands Spider Silk Manufacturing with Pursuit of Additional Rearing Center
ANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a...
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies,...
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense,...
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerabilitySAN DIEGO, Sept. 19, 2025...
The Ensign Group, Inc. Declares Quarterly Dividend of $0.0625 Per Share
SAN JUAN CAPISTRANO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group...